Press Releases Archives - Page 12 of 103 - Lupin

BSE 2356.95 NSE 2359.80

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2356.95 NSE 2359.80

Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India

September 18, 2024

Lupin Launches Mirabegron Extended-Release Tablets in the United States

September 4, 2024

Lupin Launches Doxorubicin Hydrochloride Liposome Injection in the United States

August 29, 2024

Lupin Receives Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.1%

August 27, 2024

Lupin Receives Health Canada Approval for Biosimilar Pegfilgrastim

August 23, 2024

Lupin Receives Tentative Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)

August 14, 2024

Lupin Q1 FY2025 Results

Lupin Announces Successful Completion of Phase 3 Trials for Lucentis® Biosimilar

Lupin Receives Approval from U.S. FDA for Prednisolone Acetate Ophthalmic Suspension USP

Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets

1 2 … 11 12 13 … 102 103

Search

Hit enter to search or ESC to close